Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Migraine polygenic risk score associates with efficacy of migraine-specific drugs.

< BACK TO ARCHIVE


Papers: 21 Dec 2019 - 27 Dec 2019


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2019 Dec


Neurol Genet


http://www.ncbi.nlm.nih.gov/pubmed/31872049?dopt=Abstract


5


6

Migraine polygenic risk score associates with efficacy of migraine-specific drugs.

Authors

Migraine polygenic risk score associates with efficacy of migraine-specific drugs.
Kogelman LJA, Esserlind A-L, Christensen A F, Awasthi S, Ripke S, Ingason A, Davidsson OB, Erikstrup C, Hjalgrim H, Ullum H, Olesen J, Hansen T F
Neurol Genet. 2019 Dec; 5(6):e364.
PMID: 31872049.

Abstract

To assess whether the polygenic risk score (PRS) for migraine is associated with acute and/or prophylactic migraine treatment response.
Read This Paper